India  

Covaxin out of clinical trial mode, granted restricted emergency use authorisation

IndiaTimes Thursday, 11 March 2021
The Centre on Thursday said Bharat Biotech's indigenously developed Covaxin is out of the "clinical trial mode" and that it has now been granted the regular restricted emergency use authorisation just like Covishield manufactured by Serum Institute. ​​​NITI Aayog member (Health) Dr V K Paul said Covaxin and Covishield have the same licensure status now.
0
shares
ShareTweetSavePostSend
 

You Might Like


💡 newsR Knowledge: Other News Mentions

BBV152 BBV152 Vaccine against COVID-19

Use entire national capacity to step up Covid vaccine production, PM tells officials

The PM’s directive came at a review meeting on the Covid situation on Saturday a day after he had overseen an assessment of oxygen supplies and production and..
IndiaTimes

Covaxin production to be increased to 100 million doses per month by September 2021: Centre

Union health minister Harsh Vardhan said financial support is being provided to four manufacturers to expand Covaxin vaccine production.
DNA

India to increase Covaxin production to 100 million doses per month by September

The Union government on Friday said it will amp up the production of the indigenously developed Covaxin vaccine to 100 million doses per month by September. As..
IndiaTimes
Mumbai's Haffkine Institute gets Centre's nod to produce Covaxin [Video]

Mumbai's Haffkine Institute gets Centre's nod to produce Covaxin

The Central Government has given permission to Haffkine Institute to produce Bharat Biotech's Covaxin. CM Uddhav Thackeray thanked PM Modi through a tweet by CM office, Maharashtra on April 15, "The Dept of Science and Technology, Government of India, has granted approval to Haffkine Institute to produce Bharat Biotech's Covaxin vaccine on a transfer of technology basis. CM Uddhav Balasaheb Thackeray has thanked the Hon'ble PM Shri@narendramodi for approving this request."

Credit: ANI    Duration: 01:14Published

Oxford–AstraZeneca COVID-19 vaccine Oxford–AstraZeneca COVID-19 vaccine Vaccine against COVID-19

‘Covaxin, Covishield both work against Covid's UK strain’

Both Covaxin and Covishield — the two vaccines against Covid in use in India — are effective against the UK variant, which is one the two prevailing..
IndiaTimes

Vietnam envoy takes first dose of Indian COVID-19 vaccine Covaxin

The Vietnamese envoy joins other envoys in getting vaccinated. Earlier this month, Australian envoy got vaccinated using Covishield vaccine.
DNA

COVID-19 news: India gets third vaccine as Russia's Sputnik V gets nod for emergency use

This is the third COVID-19 vaccine approved by the Subject Expert Committee (SEC) after Covishield and Covaxin.
DNA
Kerala dance trend: Vaccines shake a leg to Rasputin | Oneindia News [Video]

Kerala dance trend: Vaccines shake a leg to Rasputin | Oneindia News

Kerala police advisory for getting vaccinated is winning hearts online. Catching on to the viral Rasputin dance trend made famous by 2 spunky Kerala medical students, the state police made 2 vials of Covaxin and Covishield shake a leg to this evergreen number by Boney M. #Rasputin #KeralaDanceViral #KeralaDoctorsDance

Credit: Oneindia    Duration: 01:06Published

European Medicines Agency issues post-vax adverse-event alert for medics

The safety committee of the European Medicines Agency (EMA) has asked those receiving the AstraZeneca vaccine (called Covishield in India) and medical..
IndiaTimes

Bharat Biotech Bharat Biotech Indian biotechnology company and vaccine manufacturer

Even as Covid vaccine demand rises, firms may take some weeks to up production

Indications are that India’s vaccine production is expected to be limited for a few more weeks though a step-up is expected as Serum Institute of India and..
IndiaTimes

Serum Institute of India Serum Institute of India Indian biotechnological company, vaccine manufacturer

India gifts one lakh doses of COVID-19 vaccine to Nepal Army [Video]

India gifts one lakh doses of COVID-19 vaccine to Nepal Army

As a mark of friendship and strong ties between New Delhi and Kathmandu, India gifted one lakh doses of COVID-19 vaccines to the Nepal Army on March 28. The nine packages of Covishield vaccines, manufactured by the Serum Institute of India (SII) arrived in Kathmandu, via an Air India flight late in the evening. So far, India has provided COVID-19 vaccines to over 70 countries. India has also provided medical supplies to 150 nations in the fight during pandemic.

Credit: ANI    Duration: 01:23Published
India-made vaccine to be dispatched for Denmark [Video]

India-made vaccine to be dispatched for Denmark

A consignment of Covishield vaccine, by Serum Institute of India, to be dispatched from Mumbai's Chhatrapati Shivaji Maharaj International Airport to Denmark's Copenhagen as part of the 'Vaccine Maitri' initiative. The consignment will be loaded in A Qatar airways' flight to Doha scheduled to depart at 9.15 am on March 27. So far, India has provided COVID-19 vaccines to over 70 countries. India has also supplied medical supplies to 150 nations in the fight against pandemic.

Credit: ANI    Duration: 01:25Published
Watch: UK PM Boris Johnson gets his first jab of AstraZeneca Covid-19 vaccine [Video]

Watch: UK PM Boris Johnson gets his first jab of AstraZeneca Covid-19 vaccine

British PM Boris Johnson received his first dose of AstraZeneca's Covid vaccine on Friday. The 56-year-old UK PM took to Twitter and shared a video urging the public to do the same. Johnson received the jab at Gassiot House Outpatient Centre in London's St Thomas' Hospital. Last year, Johnson was diagnosed with Covid and was admitted to the hospital for treatment. Johnson had spent a week at St Thomas' Hospital including three days in intensive care. AstraZeneca's jab, developed with Oxford, provides the bulk of Britain's inoculation campaign. A large portion of its supply has also been produced by the Serum Institute of India.

Credit: HT Digital Content    Duration: 02:03Published

NITI Aayog NITI Aayog Indian government think tank

Remdesivir for those who are hospitalized, not to be procured from chemist shops: Niti Aayog [Video]

Remdesivir for those who are hospitalized, not to be procured from chemist shops: Niti Aayog

During press conference held in Delhi, Niti Aayog's Dr VK Paul spoke on Remdesivir, which is an anti-viral drug for COVID-19. "There is no question of use of Remdesivir in home setting. This is required for those individuals who require hospitalisation and are on oxygen. It should only be use in hospital and not to be procured from chemist shops. We appeal that there should be rational use of Remdesivir. The drug is available in sufficient numbers. We appeal to the physicians' community for rational, judicious, and correct use of the drug," said Dr VK Paul.

Credit: ANI    Duration: 02:26Published
‘Doses approved by US regulators…’: Centre on vaccines, Remdesivir use | Covid [Video]

‘Doses approved by US regulators…’: Centre on vaccines, Remdesivir use | Covid

The Centre on Tuesday said doctors should ensure "rational and judicious" use of anti-viral drug Remdesivir, underlining it is to be given only to serious COVID-19 patients in hospitals and is not to be used in home settings. NITI Aayog member (Health) Dr V K Paul said, "Remdesivir is to be used only in those who require hospitalisation and are on oxygen support. That is the precondition. There is no question of its use in the home setting and for mild cases, and it is not to be procured from chemist shops." "We appeal to physicians to ensure rational, correct and judicious use of Remdesivir in hospitalised patients," he said. Watch the full video for more details.

Credit: HT Digital Content    Duration: 06:23Published

Remdesivir 'not for home use', Centre says amid rise in demand

Addressing a media briefing on Tuesday, Niti Aayog member Dr V K Paul said Remdesivir is "only for those who require hospitalisation and oxygen. That is the..
IndiaTimes
No vaccine shortage in country: NITI Aayog [Video]

No vaccine shortage in country: NITI Aayog

While addressing a joint press conference in the national capital on March 24, the member of (Health) in NITI Aayog, Dr Vinod K Paul said there is no shortage of COVID vaccines in the country. Dr Paul said, "We have adequate supplies of vaccine for the COVID-19 vaccination program that has been brought forth." "There is no inadequacy of vaccine supply," he added.

Credit: ANI    Duration: 01:26Published

Related videos from verified sources

Doctors welcome India's approval to 'Sputnik V' vaccine [Video]

Doctors welcome India's approval to 'Sputnik V' vaccine

Subject Expert Committee of union government on April 12 approved Dr Reddy's application for emergency use authorisation to Russian COVID vaccine 'Sputnik V' in India. With this, India has now three..

Credit: ANI     Duration: 01:50Published
'COVAXIN' demonstrated efficacy of 80.6% in Phase 3 clinical trial: Bharat Biotech [Video]

'COVAXIN' demonstrated efficacy of 80.6% in Phase 3 clinical trial: Bharat Biotech

Bharat Biotech's COVID-19 vaccine, 'COVAXIN' has demonstrated an interim vaccine efficacy of 80.6% in its Phase 3 clinical trial. "Today is an important day for us, country and Indian science. COVAXIN..

Credit: ANI     Duration: 01:42Published
They thought they got the Covid-19 vaccine. They were part of a trial instead [Video]

They thought they got the Covid-19 vaccine. They were part of a trial instead

More than a dozen slum residents in Bhopal, India, say they thought they were being vaccinated for Covid-19. They say they later discovered from local activists that some of them hadn’t been given an..

Credit: Bleacher Report AOL     Duration: 03:42Published

Related news from verified sources

Centre moots single-use plastic ban next year

Seeking to make India single-use plastic-free by next year, the Centre has proposed a ban on such items in two phases beginning January 1, 2022. It issued a...
IndiaTimes

Covaxin out of clinical trial mode, granted restricted emergency use authorisation

The Centre on Thursday said Bharat Biotech's indigenously developed Covaxin is out of the "clinical trial mode" and that it has now been granted the regular...
IndiaTimes

Centre proposes easing norm for lease of forest land to non-govt entities for forestry use


IndiaTimes